RORA levels were found to be lower in tumor samples compared to normal samples in several cancers, including bladder urothelial carcinoma, invasive breast carcinoma, cholangiocarcinoma, colon cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, clear cell renal carcinoma, papillary renal cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, squamous cell lung carcinoma, pheochromocytoma, paraganglioma, prostate cancer, rectal cancer, gastric cancer, thyroid carcinoma, and endometrial carcinoma. This evidence concerns the gene RORA and prostate cancer.